Abstract
Hematological malignances, accounts for around 25 thousand every year in Brazil. Among few therapeutic options, Chimeric Antigen Receptor (CAR) T lymphocytes cell therapy has emerged as a novel and effective therapeutic practice for the treatment of B-cell Leukemia and Lymphoma. For this autologous cellular immunotherapy, T-cells derived from patient blood are bioengineered in vitro to ex…